The doctor taps Zulay
Balza's knees with a hammer and she doesn't feel a thing. She can't squeeze his
outstretched fingers or shut her eyelids. Her face is partially paralyzed.
Associated
Press report continues:
"The
weakness started in my legs and climbed upward. The face was last. After three
days, I couldn't walk," said Balza, 49. "My legs felt like
rags."
Balza
is a patient at the public University Hospital in Cucuta, at the epicenter of
the Colombian outbreak of the mosquito-borne Zika virus. Only Brazil has more
cases.
Two
weeks ago, she came under assault by Guillain-Barre (gee-YOHN-bah-RAY), a rare
and sometimes fatal affliction that is the Western world's most common cause of
general paralysis.
Alarm
over the Zika epidemic spreading across the Americas has been chiefly over
birth defects, but frontline physicians believe a surge in Guillain-Barre cases
may also be related.
The
World Health Organization says Guillain-Barre cases are on the rise in Brazil,
Colombia, El Salvador, Suriname and Venezuela, all hit hard by Zika, though a
link remains unproven.
The
auto-immune disorder historically strikes only one or two people in 100,000.
About one in 20 of those cases ends in death, and it is frightful.
"I
thought my body was going to explode," said Balza, sitting on her hospital
bed and apparently over the worst.
Guillain-Barre
attacks skeletal muscular nerves as if they were a foreign enemy. Fine motor
skills rapidly erode, arms and legs tingle and weaken to numbness. Patients
lose their balance, their speech. In rare cases, they require ventilators to
stay alive.
The
syndrome typically strikes after a bacterial or viral infection, such as
influenza, HIV or dengue, though its cause can't always be determined.
Dr.
Jairo Lizarazo, the neurologist treating Balza, has seen cases increase more
than tenfold since December — 30 cases in all — in this muggy city bordering
Venezuela. Like Balza, many patients never showed the characteristic symptoms
of Zika — fever, rashes, joint pain and conjunctivitis. Four in five don't.
He's
convinced the virus boosts susceptibility to Guillain-Barre.
"It's
an epidemiological association," said Lizarazo. "We don't know
exactly how it works. But it's there, for sure."
Associated
cases confirmed or suspected based on clinical evidence number in the hundreds.
Guillain-Barre cases believed to be linked to the virus have killed three
people in recent weeks in Colombia and health officials have attributed another
three Guillian-Barre deaths in Venezuela to suspected Zika infections.
WHO
said Zika has been confirmed present in apparently just one Guillain-Barre
death, in the northwestern Venezuela state of Zulia in January.
Dr.
Maria Lucia Brito Ferreira, chief neurologist at Hospital da Restauracao in
Recife, Brazil, said she hopes to get laboratory confirmation this month that
nine Guillain-Barre deaths recorded there in the past year were Zika-related.
Cases
of Guillain-Barre in Colombia — about 450 annually before Zika struck — were up
nearly threefold in the past month and a half.
El
Salvador has reported 118 cases since November, nearly as many as previously
seen in a year. "The only explanation is the Zika virus," said Deputy
Health Minister Eduardo Espinoza.
Dr.
Osvaldo Nascimento, a leading Rio neurologist, estimates Brazilian cases of
Guillain-Barre are up fivefold. Reporting is not compulsory, so the
government's partial figure of 1,868 cases requiring hospitalization last year
is a sketchy parameter.
An
upsurge in Guillain-Barre was documented in 2013 during a major Zika outbreak
in French Polynesia, with a study finding cases up twentyfold. WHO said all 42
cases recorded in the Pacific archipelago tested positive for Zika as well as
dengue fever, which is also currently present in Colombia, Venezuela, Brazil
and other Zika-affected countries.
Antibodies
for the dengue and chikungunya viruses, which are far more debilitating than
Zika, are often being found in infected patients. That is making establishing a
direct Zika-Guillain-Barre link more complicated.
Like
Zika, both viruses are transmitted by the Aedes aegypti mosquito and could also
trigger Guillian-Barre, experts say.
Under
normal circumstances, eight in 10 patients nearly fully recover from Guillian-Barre,
though it sometimes takes months.
Data
on Guillain-Barre is scant in most of the developing world. Of 18 countries
participating in a clinical study launched by Dutch physicians in 2012, only
two are in Latin America: Mexico and Argentina. Brazil just joined.
Across
the region, investigators were simply unable to get government funding to
participate, said Dr. Ken Gorson, a Tufts University neurologist and
president-elect of an international foundation that combats
Guillain-Barre.
Poorer
countries were ill-prepared to manage the crisis.
Colombia's
National Health Institute is overwhelmed with a weeks-long backlog in
completing tests for Zika.
The
three Guillain-Barre deaths that the country's Health Ministry attributed to
Zika on Feb. 5 have not yet been confirmed by laboratory tests, said spokesman
Ricardo Amortegui. Nor have the three deaths in the Venezuelan state of Lara
announced last week.
One
Guillian-Barre fatality in Colombia suspected of being linked to Zika was a
51-year-old man from the Caribbean island of San Andres who died in November,
said Rita Almanza, epidemiology chief in Medellin. The others were a
45-year-old man and a 41-year-old woman flown from Turbo on the Caribbean coast
who died in Medellin in February.
Guillain-Barre
grabbed hold of Nancy Pino in neighboring Venezuela with devastating effect.
The
68-year retired school administrator developed fever, rashes and muscle pain
while celebrating Christmas with her family in the hot lowland state of
Anzoategui.
She
recovered quickly. Days later, her hands and feet started to go numb. Her
tongue felt like it was asleep. She stopped eating.
The
family rushed her to a Caracas hospital. She could barely walk.
Bed-ridden,
she lost the ability to talk and soon, to breathe. Doctors attached her to a
respirator.
"It
was so quick," daughter Nihara Ramos said between sobs. "It was like
a flame consuming her from the bottom up."
Doctors
diagnosed Guillain-Barre with a spinal tap — they assumed she had Zika earlier
— and suggested that the relatives obtain immunoglobulin, an expensive
treatment that pools healthy antibodies from hundreds of donors. Gorson said it
costs US$15,000-US$45,000 in the United States.
The
family, straightjacketed by Venezuela's economic crisis, couldn't find or
afford enough.
In less than three weeks, a
woman who once bounded up seven flights of stairs to her apartment was dead.
No comments:
Post a Comment